HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical course and histopathologic risk factor assessment in patients with bilateral testicular germ cell tumors.

AbstractOBJECTIVES:
To determine whether the clinical course or the histopathologic risk factor assessment of the secondary tumor justifies early detection of the premalignant testis, since only 5% of contralateral testicular biopsies in the case of a testicular tumor reveal a testicular intraepithelial neoplasia (TIN).
METHODS:
From 1975 to 1997, 30 patients with bilateral germ cell tumors were treated; histologic and clinical data were available in all patients. In 12 patients, histopathologic re-evaluation and immunohistochemical staining of both tumors was performed for risk factor analysis.
RESULTS:
At the time the primary tumor was diagnosed, the mean patient age was 28 years. The metachronous secondary tumors were detected after a mean of 5.6 years. Seminoma was the predominant histologic finding in primary (53%) and secondary (56%) tumors. Eighty-three percent of patients had clinical Stage I (Lugano classification) disease at the diagnosis of the secondary tumor and 17% Stage II. Only 3 of 12 secondary tumors showed vascular invasion. The proliferation analysis (MIB-I score) showed a mean proliferation rate of only 34% within the primary and 26% within the secondary tumors.
CONCLUSIONS:
The results of our study show that the low clinical stage and good outcome associated with a histologic low-risk score of the secondary tumor does not mandate contralateral biopsy to detect TIN at the time of diagnosis of the first tumor.
AuthorsP Albers, A Göll, E Bierhoff, G Schoeneich, S C Müller
JournalUrology (Urology) Vol. 54 Issue 4 Pg. 714-8 (Oct 1999) ISSN: 1527-9995 [Electronic] United States
PMID10510934 (Publication Type: Journal Article, Review)
Topics
  • Adult
  • Biopsy
  • Germinoma (pathology, secondary)
  • Humans
  • Male
  • Neoplasm Staging
  • Risk Factors
  • Testicular Neoplasms (pathology, secondary)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: